

New Hampshire Medicaid Fee-for-Service (FFS) Program Prior Authorization

Adenosine triphosphate-citrate lyase inhibitor Medication

DATE OF MEDICATION REQUEST: /

| SECTION I: PATIENT INFORMATION AND MEDICATION REQUESTED | | | | | | | | | | | | | | | | | | | | | | | | | |
|------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-------|------|------|----------|-----------|------|-----|------|-------------|--------------------|------|------|----------------|-----|-----|--|-----|--|---|---|--|--|--|--|
| LAST NAME: | | | | | | | | | | FIRS | FIRST NAME: | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| ME | MEDICAID ID NUMBER: | | | | | | | | | | | | DAT | DATE OF BIRTH: | | | | | | | | | | | |
| | | | | | | | | | | | | | | |] _ | | |] _ | | | | | | | |
| GEN | NDE | R: | | Male | <u> </u> | Fen | nale | | | | 1 | | | | 1 | | | _ | | | 1 | | | | |
| Drug Name: | | | | | | | | | | | Strength: | | | | | | | | | | | | | | |
| Dosing Directions: | | | | | | | | | | | Length of Therapy: | | | | | | | | | | | | | | |
| SECTION II: PRESCRIBER INFORMATION | | | | | | | | | | | | | | | | | | | | | | | | | |
| LAST NAME: | | | | | | | | | FIRS | FIRST NAME: | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| SPECIALTY: | | | | | | | | | | NPI | NPI NUMBER: | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| PHONE NUMBER: | | | | | | | | | | FAX | FAX NUMBER: | | | | | | | | | | | | | | |
| | | | | _ | | | | - [| | | | | | | |] – | | | | _ | | | | | |
| SEC | CTIC | II NC | : CL | INI | CAL | HIST | ORY | | | | | | | | | | | | | | | | | | |
| 1. | Does the patient have heterozygous familial hypercholesterolemia (HeFH)? | | | | | | | | | | | Y | es [| No | | | | | | | | | | | |
| 2. | Does the patient have established atherosclerotic cardiovascular disease (ASCVD)? | | | | | | | | | | | Y | es [| No | | | | | | | | | | | |
| 3. | . Is the patient receiving maximally-tolerated statin? | | | | | | | | | | Y | es [| No | | | | | | | | | | | | |
| | If yes, list medication: | | | | | | | | | | _ | | | | | | | | | | | | | | |
| | . Will the patient continue to receive the statin? | | | | | | | | | | | | Y | es [| No | | | | | | | | | | |
| 5. Has the patient achieved the target LDL-C with the current regimen? | | | | | | | | | | | ∐ Y | es [| No | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |

(Form continued on the next page.)

Phone: 1-866-675-7755 © 2021–2022, Magellan Rx Management, LLC. All rights reserved. **Fax**: 1-888-603-7696 Review Date: 10/28/2022





New Hampshire Medicaid Fee-for-Service (FFS) Program Prior Authorization

Adenosine triphosphate-citrate lyase inhibitor Medication

| DATE OF MEDICATION REQUEST: / | | | | | | | | | | | | | |
|----------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|--|--|--|--|--|--|--|--|--|--|--|--|
| PATIENT LAST NAME: | PATIENT FIRST NAME: | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| SECTION III: CLINICAL HISTORY (Continued) | | | | | | | | | | | | | |
| 6. In which high-risk group would the patient be consi | dered?: | | | | | | | | | | | | |
| Extremely high risk with an LDL-C ≥ 70 mg/dL | | | | | | | | | | | | | |
| Very high risk with an LDL-C ≥ 100 mg/dL | | | | | | | | | | | | | |
| ☐ High risk with an LDL-C ≥ 130 mg/dL | | | | | | | | | | | | | |
| 7. Please list lipid panel results: | | | | | | | | | | | | | |
| 8. Is the patient a smoker? | Yes No | | | | | | | | | | | | |
| Nexlizet™ only: Is the patient currently receiving gemfibrozil? | | | | | | | | | | | | | |
| I certify that the information provided is accurate and that any falsification, omission, or concealment of ma | complete to the best of my knowledge and I understand terial fact may subject me to civil or criminal liability. | | | | | | | | | | | | |
| PRESCRIBER'S SIGNATURE: | DATE: | | | | | | | | | | | | |

Phone: 1-866-675-7755 **Fax**: 1-888-603-7696

